Literature DB >> 30478093

How I treat cancer-associated venous thromboembolism.

Noémie Kraaijpoel1, Marc Carrier2.   

Abstract

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common complication of cancer and is associated with significant morbidity and mortality. Several cancer-related risk factors contribute to the development of VTE including cancer type and stage, chemotherapy, surgery, and patient-related factors such as advanced age and immobilization. Patients with cancer frequently undergo diagnostic imaging scans for cancer staging and treatment response evaluation, which is increasing the underlying risk of VTE detection. The management of cancer-associated VTE is challenging. Over the years, important advances have been made and, recently, randomized controlled trials have been published helping clinicians' management of this patient population. In this review, we will discuss common cancer-associated VTE scenarios and critically review available evidence to guide treatment decisions.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30478093     DOI: 10.1182/blood-2018-08-835595

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Interactions between direct anticoagulants and chemotherapy.

Authors:  M Sorigue; E Sarrate; M D Miljkovic
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

2.  Coagulation Disorders: Manifestations in the Gastrointestinal Tract.

Authors:  Wolfgang Fischbach; Thomas Germer; Florian Langer; Joachim Mössner
Journal:  Visc Med       Date:  2020-07-28

Review 3.  The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.

Authors:  Tzu-Fei Wang; Jeffrey I Zwicker; Cihan Ay; Ingrid Pabinger; Anna Falanga; Darko Antic; Simon Noble; Alok A Khorana; Marc Carrier; Guy Meyer
Journal:  J Thromb Haemost       Date:  2019-07-28       Impact factor: 5.824

4.  Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors.

Authors:  Tzu-Fei Wang; Anna E Clarke; Arif A Awan; Peter Tanuseputro; Marc Carrier; Manish M Sood
Journal:  JAMA Netw Open       Date:  2022-06-01

5.  Direct Oral Anticoagulants and Cancer Thrombosis: What APs Need to Know.

Authors:  Mailey L Wilks
Journal:  J Adv Pract Oncol       Date:  2022-05-23

Review 6.  Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists.

Authors:  Marc Sorigue; Milos D Miljkovic
Journal:  J Oncol Pract       Date:  2019-12       Impact factor: 3.840

7.  The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis.

Authors:  Lu Ye; Li Cai; Yonghui Fu; Debao Zhuang; Xiaoqing Hu; Youkun Jie
Journal:  World J Surg Oncol       Date:  2021-01-13       Impact factor: 2.754

8.  Immunological analysis and differential genes screening of venous thromboembolism.

Authors:  Li-Na Gao; Qiang Li; Jian-Qin Xie; Wan-Xia Yang; Chong-Ge You
Journal:  Hereditas       Date:  2021-01-02       Impact factor: 3.271

Review 9.  Anticoagulation for atrial fibrillation in active cancer.

Authors:  Dimitrios Farmakis; Pavlos Papakotoulas; Eleni Angelopoulou; Theodoros Bischiniotis; George Giannakoulas; Panagiotis Kliridis; Dimitrios Richter; Ioannis Paraskevaidis
Journal:  Oncol Lett       Date:  2022-02-17       Impact factor: 2.967

10.  Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States.

Authors:  J D Guo; P Hlavacek; T Poretta; G Wygant; D Lane; M Gorritz; X Wang; C C Chen; R L Wade; X Pan; J Rajpura; B Stwalley; L Rosenblatt
Journal:  J Thromb Thrombolysis       Date:  2020-08       Impact factor: 2.300

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.